Alpha Cognition Inc.
Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.
Alpha Cognition Inc. (ACOG)
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2024-1103 – Consolidation - Alpha Cognition Inc. (ACOG)
le 1 novembre/November 2024
Alpha Cognition Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 6,034,221 common shares.
The name and symbol will not change.
